Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taijilidine vs sufentanil for propofol requirement in hysteroscopic surgery
ChiCTR2600126493Phase 4Not yet recruiting
- Sponsor
- Foshan Maternity & Child Healthcare Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of taijilidine in gynaecological conditions and perioperative pain (3 arms), sponsored by Foshan Maternity & Child Healthcare Hospital. Primary endpoint: Response to hysteroscopic examination. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
taijilidine
03
Conditions
gynaecological conditionsperioperative pain
Beyond the preview
Go deeper on ChiCTR2600126493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126493.